Structural Heart · Physician-Investor Briefing

Age and Early TAVR for Asymptomatic Severe Aortic Stenosis: What the Latest Data Mean for Practice and Portfolios

A closer look at how patient age reshapes the risk-benefit calculus of early intervention, and what it signals for the companies behind the valves.

Cardiology · Structural Heart Disease · 8 min read

Case Vignette

A 68-year-old asymptomatic executive with severe aortic stenosis and a peak aortic jet velocity of 4.6 m/s asks whether he should wait for symptoms or proceed now, since he feels completely well and has an upcoming board meeting he does not want to miss. His Society of Thoracic Surgeons risk score is low, his stress test is negative, and his echocardiogram shows preserved ejection fraction. This is precisely the scenario in which age-stratified trial data now offer a clearer answer than watchful waiting once did.

The Old Paradigm Is Cracking

For six decades, guidelines told clinicians to wait for symptoms before replacing a severely stenotic aortic valve.

That approach assumed intervention carried enough procedural risk to offset the danger of a diseased valve sitting quietly inside the heart.

Transcatheter aortic valve replacement has changed that math by making the procedure fast, minimally invasive, and remarkably low-risk in appropriately selected patients.

The randomized EARLY TAVR trial tested this shift directly by randomizing 901 asymptomatic patients with severe AS to either early intervention or guideline-recommended surveillance.

Primary Results at a Glance

Outcome	Early TAVR (n=455)	Clinical Surveillance (n=446)
Composite: death, stroke, or unplanned CV hospitalization	26.8%	45.3%
Death	8.4%	9.2%
Stroke	4.2%	6.7%
Unplanned CV hospitalization	20.9%	41.7%
Crossed over to AVR by 3.8 years	—	87.0%

The hazard ratio for the primary composite endpoint was 0.50, meaning early intervention roughly halved the risk compared with waiting for symptoms to appear.

Nearly nine in ten patients assigned to surveillance eventually needed valve replacement anyway, just later and after accumulating more risk along the way.

Figure 1. Key EARLY TAVR outcomes at a median follow-up of 3.8 years.

Why Age Changes the Answer

A late-breaking analysis presented at the Society for Cardiovascular Angiography and Interventions 2025 meeting asked whether a patient's age should influence the timing decision.

Older age was associated with higher rates of death, stroke, or heart failure hospitalization out to five years in both study arms, which is unsurprising on its own.

What stood out was that the relative benefit of early intervention was not confined to the elderly; it was substantial across the age spectrum, including the youngest enrolled patients.

Age-Stratified Benefit of Early TAVR

Age Group	Standout Finding at 5 Years
65–69 years	Stroke risk 0% with early TAVR vs 13% with surveillance; roughly six-fold lower rate of death, stroke, or hospitalization (4.7% vs 25.6%)
70–79 years	Consistent directional benefit with early TAVR across the composite endpoint
>80 years	Four-fold reduction in stroke with early TAVR compared with surveillance

The takeaway from the trial's lead investigators was that early TAVR should be favored over surveillance across essentially all age groups above the trial's 65-year inclusion threshold, since the composite endpoint consistently favored intervention.

This matters clinically because many physicians have intuitively reserved early intervention for older, frailer patients rather than younger ones who "still feel fine."

The data suggest the opposite framing may be more accurate: younger asymptomatic patients with severe AS may have the most to gain from acting early, particularly with respect to stroke prevention.

Figure 2. Simplified decision pathway informed by EARLY TAVR age-stratified findings.

The Market Side: Who Builds These Valves

The trial's balloon-expandable device is Edwards Lifesciences' SAPIEN platform, and the company remains the dominant player in transfemoral TAVRNYSE: EW.

Medtronic's self-expanding Evolut platform is the other major branded competitor in this spaceNYSE: MDT.

Expanding the addressable population from symptomatic to asymptomatic severe AS could meaningfully widen the eligible patient pool for both companies, since asymptomatic severe AS is common in aging populations and previously went untreated until symptoms emerged.

Structural Heart Device Makers at a Glance

Company	Ticker	Relevant Platform	Analyst Consensus	12-Month Price Target
Edwards Lifesciences	NYSE: EW	SAPIEN transcatheter valve family	Buy (27 analysts)	~$100.60 (+21% from current)
Medtronic	NYSE: MDT	Evolut self-expanding valve family	Buy (29 analysts)	~$97.84 (+16% from current)

Edwards reported second-quarter 2026 TAVR sales growth of roughly 10.5%, with overall company revenue guidance raised for the year, reflecting continued structural heart momentum even as the stock trades well below its 52-week high.

Both companies' near-term growth narratives depend partly on guideline committees eventually endorsing a broader "treat earlier" posture for asymptomatic severe AS, since current guidelines still center on symptom onset or biomarkers of decompensation as triggers for intervention.

What the Procedure Actually Costs

Cost Component	Approximate Figure
Device cost (SAPIEN 3 valve system)	~$30,000–$32,500
Median Medicare payment, full procedure	~$37,865
Median commercial insurance price	~$71,312 (varies ~2.6x by hospital and ~1.9x by insurer)
Median cash price	~$78,000

These figures come from a 2024 Circulation abstract analyzing the Turquoise Health pricing database, which found substantial regional and payer-level variation in what TAVR actually costs a given patient or system.

Extending early intervention to a much larger asymptomatic population raises legitimate health-system cost questions even though individual clinical outcomes favor earlier treatment.

Bottom Line

Age alone should no longer be the deciding factor in whether an asymptomatic patient with severe AS gets early TAVR, since benefit was consistent from the youngest enrolled patients through those over 80. The composite outcome data support a strategy shift toward earlier intervention in appropriately selected, low-surgical-risk patients rather than waiting for symptoms or crossover, which occurred in 87% of the surveillance group anyway. For the executive in the vignette above, a 68-year-old with a negative stress test and low surgical risk sits squarely inside the population that appears to benefit most, particularly regarding stroke prevention.

Physician Education Disclaimer: This article is intended for medical education purposes for physician readers and does not constitute individualized clinical guidance; treatment decisions should follow current professional society guidelines and shared decision-making with each patient.

Financial Disclaimer: Stock prices, analyst price targets, and financial data referenced above are approximate, time-sensitive, and change frequently; this content is for informational purposes only and does not constitute investment advice, and readers should consult a licensed financial advisor before making investment decisions.

Videos

NEJM: Early TAVR for Asymptomatic Severe Aortic Stenosis — trial overview

References

1. Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis, New England Journal of Medicine.
2. EARLY TAVR and EVOLVED: Early Intervention in Patients With Asymptomatic AS?, American College of Cardiology.
3. EARLY TAVR Analysis Measures Influence of Patient Age on Outcomes, Cardiac Interventions Today / SCAI 2025.
4. Prices for Transcatheter Aortic Valve Repair Vary Significantly by US Insurance Company, Circulation.
5. A Review of the Cost Effectiveness of TAVR Versus SAVR, PMC.
6. Edwards Lifesciences (EW) Stock Overview, StockAnalysis.com.
7. Medtronic (MDT) Stock Overview, StockAnalysis.com.

This article synthesizes publicly available clinical trial data, professional society summaries, and financial market data current as of late July 2026 for a physician-investor audience.